Edwards' Sapien Valve: Big Survival Boost In Those Too Sick For Surgery

Data from the first-ever randomized trial of a transcatheter aortic heart valve show a substantial one-year survival benefit for Edwards Lifesciences' Sapien versus standard medical therapy, giving the firm major momentum as it prepares to submit one of two upcoming PMAs for the device